Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer
Alessandra Gennari(Ente Ospedaliero Ospedali Galliera), Stefano Iacobelli(CTI BioPharma (Italy)), PierFranco Conte(University of Padua), Michele De Tursi(University of Chieti-Pescara), Consiglia Carella(University of Chieti-Pescara), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Cinzia Orlandini(Azienda Ospedaliera Universitaria Pisana), Enrico Ricevuto(University of L'Aquila), Paolo Bruzzi(Alleanza Contro il Cancro)
Cited by 12
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k